Related Experiment Video
Updated: May 31, 2026

Analysis of Nonhomologous End Joining and Homologous Recombination Efficiency in HEK-293T Cells Using GFP-Based Reporter Systems
Published on: February 2, 2024
Defective homologous recombination in human cancers
A Cerbinskaite1, A Mukhopadhyay, E R Plummer
1Northern Institute for Cancer Research, Newcastle University, UK. aiste.cerbinskaite@ncl.ac.uk
Abstract:
Homologous recombination (HR) is a process by which DNA double strand breaks are repaired through the alignment of homologous sequences of DNA. Interest continues to increase in HR pathway function due to the development of new therapeutic agents which selectively exploit DNA damage repair pathways. Currently the most promising of these new agents are inhibitors of poly(ADP ribose) polymerase (PARP). The response of cancers known to be deficient in HR, due to BRCA1 or 2 mutations has been demonstrated, and a wider use of PARP inhibitors in cancers with mutations of other HR pathway genes has been suggested. With ongoing clinical studies into the use of PARP inhibitors, further understanding of the HR pathway, to allow patient selection by cancer biology, is now essential. Numerous studies have investigated individual aberrations of genes involved in the HR pathway. Here we collate this evidence to give an overview of the role of the HR pathway in human cancer.
Insights
Homologous recombination (HR) DNA repair is crucial for cancer therapy. Understanding HR gene mutations aids in selecting patients for treatments like PARP inhibitors.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Homologous recombination (HR) repairs DNA double-strand breaks.
- HR pathway function is a key target for novel cancer therapeutics.
- Poly(ADP ribose) polymerase (PARP) inhibitors are promising agents exploiting DNA repair deficiencies.
Purpose of the Study:
- To provide an overview of the HR pathway's role in human cancer.
- To highlight the importance of understanding HR for patient selection in cancer therapy.
- To collate evidence on individual gene aberrations within the HR pathway.
Main Methods:
- Literature review and evidence collation.
- Analysis of studies investigating HR pathway gene aberrations.
- Synthesis of current understanding of HR in human cancer.
Main Results:
- Cancers with BRCA1/2 mutations show response to HR-targeting therapies.
- PARP inhibitors are effective in HR-deficient cancers.
- Mutations in other HR genes suggest broader applicability of PARP inhibitors.
Conclusions:
- Further understanding of the HR pathway is essential for patient stratification.
- Targeting HR offers a promising therapeutic strategy in oncology.
- Comprehensive knowledge of HR gene aberrations is critical for clinical application.
Related Concept Videos
Homologous Recombination
Homologous Recombination
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Mismatch Repair
Mismatch Repair
Fixing Double-strand Breaks

